The mean age of the NSCLC patients was 71.8 ± 8.9 years, and the median cigarette smokinghistory was 32 PY (range, 0–150 PY). Plasma CRABP2 levels were significantly higher in patients with NSCLC than in the matched controls (37.63 ± 28.71 ng/mL vs. 24.09 ± 21.09 ng/mL, P < 0.001). Higher plasma CRABP2 levels were also correlated with lower survival rates in NSCLC patients (P = 0.014).
CONCLUSION:
Plasma CRABP2 levels might be a novel diagnostic and prognostic marker in NSCLC.